MSIF Essential Medicines Panel Evidence-to-Decision Framework
Documents for the EtD framework
Last updated: 26th March 2024
Scope of MSIF Essential Medicines Panel project
Relapsing forms of multiple sclerosis (RMS)
- Evidence to decision frameworks – RMS
- Summary of European Medicines Agency (EMA) safety warnings for DMTs shortlisted for RMS
- Balance of effects excel calculations (net balance)
- Clinical feasibility from expert input for DMTs shortlisted for RMS
- Patent landscape of DMTs
- Clinical considerations
Progressive forms of multiple sclerosis (PMS)
- Evidence to decision frameworks – PMS
- Summary of European Medicines Agency (EMA) safety warnings for DMTs shortlisted for PMS
- Balance of effects excel calculations (net balance)
- Clinical feasibility from expert input for DMTs shortlisted for PMS
- Patent landscape of DMTs
- Clinical considerations
Summary of DMTs proposed in EML application